Wielokierunkowe działanie winpocetyny i korzyści z tym związane w świetle badań eksperymentalnych i klinicznych Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
mar 31, 2013
Słowa kluczowe:
winpocetyna, otępienie, udar niedokrwienny mózgu
##plugins.themes.bootstrap3.article.main##
Abstrakt
W prezentowanym artykule przedstawiono wielokierunkowy mechanizm działania winpocetyny oraz dokonano przeglądu badań przedklinicznych i klinicznych. Szczególną uwagę poświęcono danym dotyczącym skuteczności i profilu bezpieczeństwa leku. Na uwagę zasługują wyniki badań z randomizacją, w których autorzy niejednokrotnie podkreślają potrzebę przeprowadzenia kolejnych prób o wysokiej wiarygodności klinicznej z udziałem dużych grup pacjentów, poddawanych długotrwałej terapii wyższymi dawkami leku niż obecnie zarejestrowane i stosowane w codziennej praktyce klinicznej.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Zaremba, M., & Postuła , M. (2013). Wielokierunkowe działanie winpocetyny i korzyści z tym związane w świetle badań eksperymentalnych i klinicznych . Medycyna Faktów , 6(1(18), 30-41. Pobrano z https://www.journalsmededu.pl/index.php/jebm/article/view/2425
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Lorincz C., Szasz K., Kisfaludy L.: The synthesis of ethyl apovincaminate. Arzneimittelforschung 1976; 26: 1907.
2. Vinpocetine. Altern. Med. Rev. 2002; 7: 240-243.
3. Karpati E., Biro K., Kukorelli T.: [Investigation of vasoactive agents with indole skeletons at Richter Ltd]. Acta Pharm. Hung. 2002; 72: 25-36.
4. Bereczki D., Fekete I.: A systematic review of vinpocetine therapy in acute ischaemic stroke. Eur. J. Clin. Pharmacol. 1999; 55: 349-352.
5. Hadjiev D., Yancheva S.: Rheoencephalographic and psychological studies with ethyl apovincaminate in cerebral vascular insufficiency. Arzneimittelforschung 1976; 26: 1947-1950.
6. Ribari O., Zelen B., Kollar B.: Ethyl apovincaminate in the treatment of sensorineuronal impairment of hearing. Arzneimittelforschung 1976; 26: 1977-1980.
7. Szobor A., Klein M.: Ethyl apovincaminate therapy in neurovascular diseases. Arzneimittelforschung 1976; 26: 1984-1989.
8. Kaham A., Olah M.: Use of ethyl apovincaminate in ophthalmological therapy. Arzneimittelforschung 1976; 26: 1969-1972.
9. Nosalova V., Machova J., Babulova A.: Protective action of vinpocetine against experimentally induced gastric damage in rats. Arzneimittelforschung 1993; 43: 981-985.
10. Miyata N., Yamaura H., Tanaka M., Muramatsu M., Tsuchida K., Okuyama S., Otomo S.: Effects of VA-045, a novel apovincaminic acid derivative, on isolated blood vessels: cerebroarterial selectivity. Life Sci. 1993; 52: 181-186.
11. Sitges M., Galván E., Nekrassov V.: Vinpocetine blockade of sodium channels inhibits the rise in sodium and calcium induced by 4-aminopyridine in synaptosome. Neurochem. Int. 2005; 46: 533-540.
12. Lynch J.J., Yu S.P., Canzoniero L.M. et al.: Sodium channel blocker reduce oxygen-glucose deprivation – induced cortical neuron injury when combined with glutamate receptor antagonists. J. Pharmacol. Exp. Ther. 1995; 273: 554-560.
13. Tárnok K., Kiss E., Luiten P.G., Nyakas C., Tihanyi K., Schlett K., Eisel U.L.: Effects of Vinpocetine on mitochondrial function and neuroprotection in primary cortical neurons. Neurochem. Int. 2008; 53: 289-295.
14. Stolc S.: Indole derivatives as neuroprotectants. Life Sci. 1999; 65: 1943-1950.
15. Hagiwara M., Endo T., Hidaka H.: Effects of vinpocetine on cyclic nucleotide metabolism in vascular smooth muscle. Biochem. Pharmacol. 1984; 33: 453-457.
16. Truss M.C., Uckert S., Stief C.G., Forssmann W.G., Jonas U.: Cyclic nucleotide phosphodiesterase (PDE) isoenzymes in the human detrusor smooth muscle. II. Effect of various PDE inhibitors on smooth muscle tone and cyclic nucleotide levels in vitro. Urol. Res. 1996; 24: 129-134.
17. Jeon K.I., Xu X., Aizawa T., Lim J.H., Jono H., Kwon D.S., Abe J. et al.: Vinpocetine inhibits NF-кB dependent inflammation via an IKK-dependent but PDE-independent mechanism. Proc. Natl. Acad. Sci. USA 2010; 107: 9795-9800.
18. Matsukawa M., Ogawa M., Nakadate K., Maeshima T., Ichitani Y., Kawai N.: Serotonin and acetylcholine are crucial to maintain hippocampal synapses and memory acquisition in rats. Neurosci. Lett. 1997; 230: 13-16.
19. Shibuya T., Sato K.: Effects of vinpocetine on experimental brain ischemia, histological study of brain monomines. Igaku No Ayumi 1986; 139: 217-219.
20. Trejo F., Nekrassov V., Sitges M.: Characterization of vinpocetine effects on DA and DOPAC release in striatal isolated nerve endings. Brain Res. 2001; 909: 59-67.
21. Milusheva E., Sperlagh B., Kiss B., Szporny L., Pásztor E., Papasova M., Vizi E.S.: Inhibitory effect of hypoxic condition on acetylcholine release is partly due to the effect of adenosine released from the tissue. Brain Res. Bull. 1990; 24: 369-373.
22. Kuzuya F., Osawa M., Maruyama S.: Effects of vinpocetine on blood viscosity and platelet aggregability. Today’s Therapy Trends 1985; 1: 21-29.
23. Csillik B., Mihály A., Knyihár-Csillik E.: Antinociceptive effect of vinpocetine – a comprehensive survey. Ideggyogy Sz. 2010; 63: 185-192.
24. DeNoble V.J., Repetti S.J., Gelpke L.W., Wood L.M., Keim K.L.: Vinpocetine: nootropic effects on scopolamineinduced and hypoxia-induced retrieval deficits of a step-through passive avoidance response in rats. Pharmacol. Biochem. Behav. 1986; 24: 1123-1128.
25. Nyakas C., Felszeghy K., Szabó R., Keijser J.N., Luiten P.G., Szombathelyi Z., Tihanyi K.: Neuroprotective effects of vinpocetine and its major metabolite cis-apovincaminic acid on NMDA-induced neurotoxicity in a rat entorhinal cortex lesion model. CNS Neurosci. Ther. 2009; 15: 89-99.
26. Deshmukh R., Sharma V., Mehan S., Sharma N., Bedi K.L.: Amelioration of intracerebroventricular streptozotocin induced cognitive dysfunction and oxidative stress by vinpocetine – a PDE1 inhibitor. Eur. J. Pharmacol. 2009; 620: 49-56.
27. Pereira C., Agostinho P., Moreira P.I., Duarte A.I., Santos M.S., Oliveira C.R.: Neuroprotection strategies: effect of vinpocetine in vitro oxidative stress models (Portuguese). Acta Med. Port. 2003; 16: 401-406.
28. Pereira C., Agostinho P., Oliveira C.R.: Vinpocetine attenuates the metabolic dysfunction induced by amyloid betapeptides in PC12 cells. Free Radic. Res. 2000; 33: 497-506.
29. Thal L.J., Salmon D.P., Lasker B., Bower D., Klauber M.R.: The safety and lack of efficacy of vinpocetine in Alzheimer’s disease. J. Am. Geriatr. Soc. 1989; 37: 515-520.
30. Szatmari S.Z., Whitehouse P.J.: Vinpocetine for cognitive impairment and dementia. Cochrane Database Syst. Rev. 2003; 1: CD003119.
31. Valikovics A.: [Investigation of the effect of vinpocetine on cerebral blood flow and cognitive functions]. Ideggyogy Sz. 2007; 60: 301-310.
32. Tohgi H., Sasaki K., Chiba K., Nozaki Y.: Effect of vinpocetine on oxygen release of hemoglobin and erythrocyte organic polyphosphate concentrations in patients with vascular dementia of the Binswanger type. Arzneimittelforschung 1990; 40: 640-643.
33. Balestreri R., Fontana L., Astengo F.: A double-blind placebo controlled evaluation of the safety and efficacy of vinpocetine in the treatment of patients with chronic vascular senile cerebral dysfunction. J. Am. Geriatr. Soc. 1987; 35: 425-430.
34. Valikovics A., Csányi A., Németh L.: Study of the effects of vinpocetin on cognitive functions. Ideggyogy Sz. 2011; 64: 115-120.
35. Olpe H.R., Steinmann M.W., Jones R.S.G.: Locus coeruleus as a target for psychogeriatric agents. Ann. N.Y. Acad. Sci. 1985; 444: 399-405.
36. Gaal L., Molnar P.: Effect of vinpocetine on noradrenergic neurons in rat locus coeruleus. Eur. J. Pharmacol. 1990; 187: 537-539.
37. McDaniel M.A., Maier S.F., Einstein G.O.: Brain-specific nutrients: a memory cure? Nutrition 2003; 19: 957-975.
38. Subhan Z., Hindmarch I.: Psychopharmacological effects of vinpocetine in normal healthy volunteers. Eur. J. Clin. Pharmacol. 1985; 28: 567-571.
39. Polich J., Gloria R.: Cognitive effects of a Ginkgo biloba/vinpocetine compound in normal adults: systematic assessment of perception, attention and memory. Hum. Psychopharmacol. 2001; 16: 409-416.
40. Dutov A.A., Tolpyshev B.A., Karpov V.N., Petrov A.P.: [Effect of Cavinton on convulsions caused by chemical substances]. Farmakol. Toksikol. 1986; 49: 22-25.
41. Nekrassov V., Sitges M.: Vinpocetine inhibits the epileptic cortical activity and auditory alterations induced by pentylenetetrazole in the guinea pig in vivo. Epilepsy Res. 2004; 60: 63-71.
42. Sitges M., Nekrassov V.: Vinpocetine prevents 4-aminopyridine-induced changes in the EEG, the auditory brainstem responses and hearing. Clin. Neurophysiol. 2004; 115: 2711-2717.
43. Sitges M., Guarneros A., Nekrassov V.: Effects of carbamazepine, phenytoin, valproic acid, oxcarbazepine, lamotrigine, topiramate and vinpocetine on the presynaptic Ca2+ channel-mediated release of [3H]glutamate: comparison with the Na+ channel-mediated release. Neuropharmacol. 2007; 53: 854-862.
44. Dutov A.A., Tolpyshev B.A., Petrov A.P., Gladun V.N.: [Use of cavinton in epilepsy]. Zh. Nevropatol. Psikhiatr. Im. S.S. Korsakova 1986; 86: 850-855.
45. Dutov A.A., Gal’tvanitsa G.A., Volkova V.A., Sukhanova O.N., Lavrishcheva T.G., Petrov A.P.: [Cavinton in the prevention of the convulsive syndrome in children after birth injury]. Zh. Nevropatol. Psikhiatr. Im. S.S. Korsakova 1991; 91: 21-22.
46. Otroshchenko N.: [Psychopharmacotherapy in combine treatment of depressive disorders in patients with brain pathology affected by the Chernobyl Atomic Electric Power Station accident]. Lik. Sprava. 2000; 6: 8-10.
47. Hindmarch I., Fuchs H.H., Erzigkeit H.: Efficacy and tolerance of vinpocetine in ambulant patients suffering from mild to moderate organic psychosyndromes. Int. Clin. Psychopharmacol. 1991; 6: 31-43.
48. Dézsi L., Kis-Varga I., Nagy J., Komlódi Z., Kárpáti E.: [Neuroprotective effects of vinpocetine in vivo and in vitro. Apovincaminic acid derivatives as potential therapeutic tools in ischemic stroke]. Acta Pharm. Hung. 2002; 72: 84-91.
49. Zhou X., Dong X., Crona J., Maguire M., Priestley T.: Vinpocetine is a potent blocker of rat NaV1.8 Tetrodotoxin-Resistant sodium Channels. JPET 2003; 306: 498-504.
50. Zelles T., Franklin L., Koncz I., Lendvai B., Zsilla G.: The nootropic drug vinpocetine inhibits veratridine – induced [Ca2+] increase in rat hippocampal CA1 pyramidal cells. Neurochem. Res. 2001; 26: 1095-1100.
51. Bonoczk P., Gulyas B., Adam-Vizi V., Nemes A., Karpati E., Kiss B., Kapas M., Szantay C., Koncz I., Zelles T., Vas A.: Role of sodium channel inhibition in neuroprotection: Effect of vinpocetine. Brain Research Bulletin 2000; 53: 245-254.
52. Katsuta K., Umemura K., Ueyama N., Matsuoka N.: Pharmacological evidence for a correlation between hippocampal CA1 cell damage and hyperlocomotion following global cerebral ischemia in gerbils. Eur. J. Pharmacol. 2003; 467: 103-109.
53. Maslarova J., Nikolov R.: Antihypoxic effect of vinpocetine. Works of the Chemical Pharmaceutical Research Institute, 1999; XIX: 175-182.
54. Lamar J.C., Poignet H., Beaughard M.: Calcium antagonist activity of vinpocetine and vincamine in several models of cerebral ischemia. Drug. Develop. Res. 1988; 14: 297-304.
55. Rischke R., Krieglstein J.: Protective effect of vinpocetine against brain damage caused by ischemia. Jpn J. Pharmacol. 1991; 56: 349-356.
56. Krieglstein J., Rischke R.: Vinpocetine increases the neuroprotective effect of adenosine in vitro. Eur. J. Pharmacol. 1991; 205: 7-10.
57. Szmolenszky T., Török B.: Effect of ethyl apovincaminate on cerebral, cardiac and renal flow rate in dogs in the course of administration. Arzneimittelforschung 1976; 26: 1914-1917.
58. Romodanov A.P., Potapov A.I.: [The dynamic changes in the regional volumetric cerebral blood flow and local vascular reactivity in acute craniocerebral trauma in animals with alloxan diabetes]. Zh. Vopr. Neirokhir. Im. N.N. Burdenko 1990; 3: 19-22.
59. Hadjiev D.: Asymptomatic ischemic cerebrovascular disorders and neuroprotection with vinpocetine. Ideggyogy Sz. 2003; 56: 166-172.
60. Feigin V.L., Doronin B.M., Popova T.F. et al.: Vinpocetine treatment in acute ischaemic stroke: a pilot single-blind randomized clinical trial. Eur. J. Neurol. 2001; 8: 81-85.
61. Bereczki D., Fekete I.: Vinpocetine for acute ischaemic stroke. Cochrane Database Syst. Rev. 2000; 2: CD000480.
62. Solti F., Iskum M., Czakó E.: Effect of ethyl apovincaminate on the cerebral circulation. Studies in patients with obliterative cerebral arterial disease. Arzneimittelforschung 1976; 26: 1945-1947.
63. Miyazaki M.: The effect of cerebral vasodilator, vinpocetine, on cerebral vascular resistance evaluated by the Doppler ultrasonic technique in patients with cerebrovascular diseases. Angiology 1995; 46: 53-58.
64. Hadjiev D., Yancheva S.: Rheoencephalographic and psychological studies with ethyl apovincaminate in cerebral vascular insufficiency. Arzneimittelforschung 1976; 26: 1947-1950.
65. Feher G., Koltai K., Kesmarky G., Horvath B., Toth K., Komoly S., Szapary L.: Effect of parenteral or oral vinpocetine on the hemorheological parameters of patients with chronic cerebrovascular diseases. Phytomedicine 2009; 16: 111-117.
66. Szapáry L., Horváth B., Alexy T., Márton Z., Késmárky G., Szóts M., Nagy F. et al.: [Effect of vinpocetin on the hemorheologic parameters in patients with chronic cerebrovascular disease]. Orv. Hetil. 2003; 144: 973-978.
67. Hayakawa M.: Comparative efficacy of vinpocetine, pentoxifylline and nicergoline on red blood cell deformability. Arzneimittelforschung 1992; 42: 108-110.
68. Burtsev E.M., Savkov V.S., Shprakh V.V., Burtsev M.E.: [10-years experience with using Cavinton in cerebrovascular disorders]. Zh. Nevropatol. Psikhiatr. Im. S.S. Korsakova 1992; 92: 56-60.
69. Bereczki D., Fekete I.: Vinpocetine for acute ischemic stroke. Stroke 2008; 39: 2404-2405.
70. Salvemini D., Misko T.P., Masferrer J.L. et al.: Nitric oxide activates cyclooxygenase enzymes. Proc. Natl. Acad. Sci. USA 1993; 90: 7240-7244.
71. Olah V.A., Balla G., Balla J., Szabolcs A., Karmazsin L.: An in vitro study of the hydroxyl scavenger effect of Cavinton. Acta Paediatr. Hung. 1990; 30: 309-316.
72. Santos M., Duarte A., Moreira P., Oliveira C.: Synaptosomal response to oxidative stress: effect of vinpocetine. Free Radic. Res. 2000; 32: 57-66.
73. Gabryel B., Adamek M., Pudelko A., Malecki A., Trzeciak H.: Piracetam and vinpocetine exert cytoprotective activity and prevent apoptosis of astrocytes in vitro in hypoxia and reoxygenation. Neurotoxicology 2002; 23: 19-31.
74. Kolarov G., Orbetsova M., Nalbanski B. et al.: Complex effects of cavinton on climacteric symptoms. Akush. Ginekol. 2001; 42: 37-41.
75. Kiss E.: Adjuvant effect of cavinton in the treatment of climacteric symptoms. Ther. Hung. 1990; 38: 170-173.
76. Nekrassov V., Sitges M.: Vinpocetine protects from aminoglycoside antibiotic-induced hearing loss in guinea pig in vivo. Brain Res. 2000; 868: 222-229.
77. Maliavina U.S., Ovchinnikov I.U.M., Fasenko V.P., Maliev B.M., Kalinina M.V., Dadasheva B.B.: [Cavinton prevention of neurosensory hypoacousis in patients with different forms of tuberculosis]. Vestn. Otorinolaringol. 2003; 3: 35-40.
78. Jasper A.: Action of cavinton on hearing defects of different origin. Hung. Med. 1978; 26: 181-184.
79. Truss M., Stief C., Uckert S. et al.: Phosphodiesterase 1 inhibition in the treatment of lower urinary tract dysfunction: from bench to bedside. World J. Urol. 2001; 19: 344-350.
80. Truss M., Stief C., Uckert S. et al.: Initial clinical experience with the selective phosphodiesterase-I isoenzyme inhibitor vinpocetine in the treatment of urge incontinence and low compliance bladder. World J. Urol. 2000; 18: 439-443.
81. Csillik B., Mihály A., Knyihár-Csillik E.: Antinociceptive effect of vinpocetine – a comprehensive survey. Ideggyogy Sz. 2010; 63: 185-192.
82. Lohmann A., Dingler E., Sommer W., Schaffler K., Wober W., Schmidt W.: Bioavailability of vinpocetine and interference of the time of application with food intake. Arzneimittelforschung 1992; 42, 914-917.
83. Miskolczi P., Korma K., Polgar M., Vereczkey L.: Pharmacokinetics of vinpocetine and its main metabolite apovincaminic acid before and after the chronic oral administration of vinpocetine to humans. Eur. J. Drug. Metab. Pharmacokinet. 1990; 15: 1-5.
84. Vereczkey L.: Pharmacokinetics and metabolism of vincamine and related compounds. Eur. J. Drug. Metab. Pharmacokinet. 1985; 10: 89-103.
85. Skoromets A.A., Tanashian M.M., Chukanova E.I., Petrova E.A., Spirin N.N., Nikonov A.A., Peverennova I.E., Levin I.I.: [A multicenter program on assessment of efficacy and safety of a new therapeutic scheme for patients with chronic cerebrovascular insufficiency]. Zh. Nevrol. Psikhiatr. Im. S.S. Korsakova 2009; 109: 44-48.
86. Szakáll S., Boros I., Balkay L., Emri M., Fekete I., Kerényi L., Lehel S. et al.: Cerebral effects of a single dose of intravenous vinpocetine in chronic stroke patients: A PET study. J. Neuroimaging. 1998; 8: 197-204.
87. Charakterystyka Produktu Leczniczego Cavinton Forte 10 mg, tabletki; z dnia 23.04.2008.
88. Shimizu Y., Saitoh K., Nakayama M.: Agranulocytosis induced by vinpocetine. Medicine Online.
89. Akopov S.E., Gabrielian E.S.: Effects of aspiryn, dipyramidole, nifedipine and cavinton chich act on platet aggregation induced by diffrent aggregating agents alone and in combination. Eur. J. Clin. Pharmacol. 1992; 42: 257-259.
90. Hitzenberger G., Schmid R., Braun W., Grandt R.: Vinpocetine therapy does not change imipramine pharmacokinetics in man. Int. J. Clin. Pharmacol. Ther. Toxicol. 1990; 28: 99-104.
91. Grandt R., Braun W., Schulz H.U., Lührmann B., Frercks H.J.: Glibenclamide steady state plasma levels during concomitant vinpocetine administration in type II diabetic patients. Arzneimittelforschung 1989; 39: 1451-1454.
92. Storm G., Oosterhuis B., Sollie F.A.E., Visscher H.W., Sommer W., Beitinger H., Jonkman J.H.G.: Lack of pharmacokinetic interaction between vinpocetine and oxazepam. Br. J. Clin. Pharmcol. 1994; 38: 143-146.
2. Vinpocetine. Altern. Med. Rev. 2002; 7: 240-243.
3. Karpati E., Biro K., Kukorelli T.: [Investigation of vasoactive agents with indole skeletons at Richter Ltd]. Acta Pharm. Hung. 2002; 72: 25-36.
4. Bereczki D., Fekete I.: A systematic review of vinpocetine therapy in acute ischaemic stroke. Eur. J. Clin. Pharmacol. 1999; 55: 349-352.
5. Hadjiev D., Yancheva S.: Rheoencephalographic and psychological studies with ethyl apovincaminate in cerebral vascular insufficiency. Arzneimittelforschung 1976; 26: 1947-1950.
6. Ribari O., Zelen B., Kollar B.: Ethyl apovincaminate in the treatment of sensorineuronal impairment of hearing. Arzneimittelforschung 1976; 26: 1977-1980.
7. Szobor A., Klein M.: Ethyl apovincaminate therapy in neurovascular diseases. Arzneimittelforschung 1976; 26: 1984-1989.
8. Kaham A., Olah M.: Use of ethyl apovincaminate in ophthalmological therapy. Arzneimittelforschung 1976; 26: 1969-1972.
9. Nosalova V., Machova J., Babulova A.: Protective action of vinpocetine against experimentally induced gastric damage in rats. Arzneimittelforschung 1993; 43: 981-985.
10. Miyata N., Yamaura H., Tanaka M., Muramatsu M., Tsuchida K., Okuyama S., Otomo S.: Effects of VA-045, a novel apovincaminic acid derivative, on isolated blood vessels: cerebroarterial selectivity. Life Sci. 1993; 52: 181-186.
11. Sitges M., Galván E., Nekrassov V.: Vinpocetine blockade of sodium channels inhibits the rise in sodium and calcium induced by 4-aminopyridine in synaptosome. Neurochem. Int. 2005; 46: 533-540.
12. Lynch J.J., Yu S.P., Canzoniero L.M. et al.: Sodium channel blocker reduce oxygen-glucose deprivation – induced cortical neuron injury when combined with glutamate receptor antagonists. J. Pharmacol. Exp. Ther. 1995; 273: 554-560.
13. Tárnok K., Kiss E., Luiten P.G., Nyakas C., Tihanyi K., Schlett K., Eisel U.L.: Effects of Vinpocetine on mitochondrial function and neuroprotection in primary cortical neurons. Neurochem. Int. 2008; 53: 289-295.
14. Stolc S.: Indole derivatives as neuroprotectants. Life Sci. 1999; 65: 1943-1950.
15. Hagiwara M., Endo T., Hidaka H.: Effects of vinpocetine on cyclic nucleotide metabolism in vascular smooth muscle. Biochem. Pharmacol. 1984; 33: 453-457.
16. Truss M.C., Uckert S., Stief C.G., Forssmann W.G., Jonas U.: Cyclic nucleotide phosphodiesterase (PDE) isoenzymes in the human detrusor smooth muscle. II. Effect of various PDE inhibitors on smooth muscle tone and cyclic nucleotide levels in vitro. Urol. Res. 1996; 24: 129-134.
17. Jeon K.I., Xu X., Aizawa T., Lim J.H., Jono H., Kwon D.S., Abe J. et al.: Vinpocetine inhibits NF-кB dependent inflammation via an IKK-dependent but PDE-independent mechanism. Proc. Natl. Acad. Sci. USA 2010; 107: 9795-9800.
18. Matsukawa M., Ogawa M., Nakadate K., Maeshima T., Ichitani Y., Kawai N.: Serotonin and acetylcholine are crucial to maintain hippocampal synapses and memory acquisition in rats. Neurosci. Lett. 1997; 230: 13-16.
19. Shibuya T., Sato K.: Effects of vinpocetine on experimental brain ischemia, histological study of brain monomines. Igaku No Ayumi 1986; 139: 217-219.
20. Trejo F., Nekrassov V., Sitges M.: Characterization of vinpocetine effects on DA and DOPAC release in striatal isolated nerve endings. Brain Res. 2001; 909: 59-67.
21. Milusheva E., Sperlagh B., Kiss B., Szporny L., Pásztor E., Papasova M., Vizi E.S.: Inhibitory effect of hypoxic condition on acetylcholine release is partly due to the effect of adenosine released from the tissue. Brain Res. Bull. 1990; 24: 369-373.
22. Kuzuya F., Osawa M., Maruyama S.: Effects of vinpocetine on blood viscosity and platelet aggregability. Today’s Therapy Trends 1985; 1: 21-29.
23. Csillik B., Mihály A., Knyihár-Csillik E.: Antinociceptive effect of vinpocetine – a comprehensive survey. Ideggyogy Sz. 2010; 63: 185-192.
24. DeNoble V.J., Repetti S.J., Gelpke L.W., Wood L.M., Keim K.L.: Vinpocetine: nootropic effects on scopolamineinduced and hypoxia-induced retrieval deficits of a step-through passive avoidance response in rats. Pharmacol. Biochem. Behav. 1986; 24: 1123-1128.
25. Nyakas C., Felszeghy K., Szabó R., Keijser J.N., Luiten P.G., Szombathelyi Z., Tihanyi K.: Neuroprotective effects of vinpocetine and its major metabolite cis-apovincaminic acid on NMDA-induced neurotoxicity in a rat entorhinal cortex lesion model. CNS Neurosci. Ther. 2009; 15: 89-99.
26. Deshmukh R., Sharma V., Mehan S., Sharma N., Bedi K.L.: Amelioration of intracerebroventricular streptozotocin induced cognitive dysfunction and oxidative stress by vinpocetine – a PDE1 inhibitor. Eur. J. Pharmacol. 2009; 620: 49-56.
27. Pereira C., Agostinho P., Moreira P.I., Duarte A.I., Santos M.S., Oliveira C.R.: Neuroprotection strategies: effect of vinpocetine in vitro oxidative stress models (Portuguese). Acta Med. Port. 2003; 16: 401-406.
28. Pereira C., Agostinho P., Oliveira C.R.: Vinpocetine attenuates the metabolic dysfunction induced by amyloid betapeptides in PC12 cells. Free Radic. Res. 2000; 33: 497-506.
29. Thal L.J., Salmon D.P., Lasker B., Bower D., Klauber M.R.: The safety and lack of efficacy of vinpocetine in Alzheimer’s disease. J. Am. Geriatr. Soc. 1989; 37: 515-520.
30. Szatmari S.Z., Whitehouse P.J.: Vinpocetine for cognitive impairment and dementia. Cochrane Database Syst. Rev. 2003; 1: CD003119.
31. Valikovics A.: [Investigation of the effect of vinpocetine on cerebral blood flow and cognitive functions]. Ideggyogy Sz. 2007; 60: 301-310.
32. Tohgi H., Sasaki K., Chiba K., Nozaki Y.: Effect of vinpocetine on oxygen release of hemoglobin and erythrocyte organic polyphosphate concentrations in patients with vascular dementia of the Binswanger type. Arzneimittelforschung 1990; 40: 640-643.
33. Balestreri R., Fontana L., Astengo F.: A double-blind placebo controlled evaluation of the safety and efficacy of vinpocetine in the treatment of patients with chronic vascular senile cerebral dysfunction. J. Am. Geriatr. Soc. 1987; 35: 425-430.
34. Valikovics A., Csányi A., Németh L.: Study of the effects of vinpocetin on cognitive functions. Ideggyogy Sz. 2011; 64: 115-120.
35. Olpe H.R., Steinmann M.W., Jones R.S.G.: Locus coeruleus as a target for psychogeriatric agents. Ann. N.Y. Acad. Sci. 1985; 444: 399-405.
36. Gaal L., Molnar P.: Effect of vinpocetine on noradrenergic neurons in rat locus coeruleus. Eur. J. Pharmacol. 1990; 187: 537-539.
37. McDaniel M.A., Maier S.F., Einstein G.O.: Brain-specific nutrients: a memory cure? Nutrition 2003; 19: 957-975.
38. Subhan Z., Hindmarch I.: Psychopharmacological effects of vinpocetine in normal healthy volunteers. Eur. J. Clin. Pharmacol. 1985; 28: 567-571.
39. Polich J., Gloria R.: Cognitive effects of a Ginkgo biloba/vinpocetine compound in normal adults: systematic assessment of perception, attention and memory. Hum. Psychopharmacol. 2001; 16: 409-416.
40. Dutov A.A., Tolpyshev B.A., Karpov V.N., Petrov A.P.: [Effect of Cavinton on convulsions caused by chemical substances]. Farmakol. Toksikol. 1986; 49: 22-25.
41. Nekrassov V., Sitges M.: Vinpocetine inhibits the epileptic cortical activity and auditory alterations induced by pentylenetetrazole in the guinea pig in vivo. Epilepsy Res. 2004; 60: 63-71.
42. Sitges M., Nekrassov V.: Vinpocetine prevents 4-aminopyridine-induced changes in the EEG, the auditory brainstem responses and hearing. Clin. Neurophysiol. 2004; 115: 2711-2717.
43. Sitges M., Guarneros A., Nekrassov V.: Effects of carbamazepine, phenytoin, valproic acid, oxcarbazepine, lamotrigine, topiramate and vinpocetine on the presynaptic Ca2+ channel-mediated release of [3H]glutamate: comparison with the Na+ channel-mediated release. Neuropharmacol. 2007; 53: 854-862.
44. Dutov A.A., Tolpyshev B.A., Petrov A.P., Gladun V.N.: [Use of cavinton in epilepsy]. Zh. Nevropatol. Psikhiatr. Im. S.S. Korsakova 1986; 86: 850-855.
45. Dutov A.A., Gal’tvanitsa G.A., Volkova V.A., Sukhanova O.N., Lavrishcheva T.G., Petrov A.P.: [Cavinton in the prevention of the convulsive syndrome in children after birth injury]. Zh. Nevropatol. Psikhiatr. Im. S.S. Korsakova 1991; 91: 21-22.
46. Otroshchenko N.: [Psychopharmacotherapy in combine treatment of depressive disorders in patients with brain pathology affected by the Chernobyl Atomic Electric Power Station accident]. Lik. Sprava. 2000; 6: 8-10.
47. Hindmarch I., Fuchs H.H., Erzigkeit H.: Efficacy and tolerance of vinpocetine in ambulant patients suffering from mild to moderate organic psychosyndromes. Int. Clin. Psychopharmacol. 1991; 6: 31-43.
48. Dézsi L., Kis-Varga I., Nagy J., Komlódi Z., Kárpáti E.: [Neuroprotective effects of vinpocetine in vivo and in vitro. Apovincaminic acid derivatives as potential therapeutic tools in ischemic stroke]. Acta Pharm. Hung. 2002; 72: 84-91.
49. Zhou X., Dong X., Crona J., Maguire M., Priestley T.: Vinpocetine is a potent blocker of rat NaV1.8 Tetrodotoxin-Resistant sodium Channels. JPET 2003; 306: 498-504.
50. Zelles T., Franklin L., Koncz I., Lendvai B., Zsilla G.: The nootropic drug vinpocetine inhibits veratridine – induced [Ca2+] increase in rat hippocampal CA1 pyramidal cells. Neurochem. Res. 2001; 26: 1095-1100.
51. Bonoczk P., Gulyas B., Adam-Vizi V., Nemes A., Karpati E., Kiss B., Kapas M., Szantay C., Koncz I., Zelles T., Vas A.: Role of sodium channel inhibition in neuroprotection: Effect of vinpocetine. Brain Research Bulletin 2000; 53: 245-254.
52. Katsuta K., Umemura K., Ueyama N., Matsuoka N.: Pharmacological evidence for a correlation between hippocampal CA1 cell damage and hyperlocomotion following global cerebral ischemia in gerbils. Eur. J. Pharmacol. 2003; 467: 103-109.
53. Maslarova J., Nikolov R.: Antihypoxic effect of vinpocetine. Works of the Chemical Pharmaceutical Research Institute, 1999; XIX: 175-182.
54. Lamar J.C., Poignet H., Beaughard M.: Calcium antagonist activity of vinpocetine and vincamine in several models of cerebral ischemia. Drug. Develop. Res. 1988; 14: 297-304.
55. Rischke R., Krieglstein J.: Protective effect of vinpocetine against brain damage caused by ischemia. Jpn J. Pharmacol. 1991; 56: 349-356.
56. Krieglstein J., Rischke R.: Vinpocetine increases the neuroprotective effect of adenosine in vitro. Eur. J. Pharmacol. 1991; 205: 7-10.
57. Szmolenszky T., Török B.: Effect of ethyl apovincaminate on cerebral, cardiac and renal flow rate in dogs in the course of administration. Arzneimittelforschung 1976; 26: 1914-1917.
58. Romodanov A.P., Potapov A.I.: [The dynamic changes in the regional volumetric cerebral blood flow and local vascular reactivity in acute craniocerebral trauma in animals with alloxan diabetes]. Zh. Vopr. Neirokhir. Im. N.N. Burdenko 1990; 3: 19-22.
59. Hadjiev D.: Asymptomatic ischemic cerebrovascular disorders and neuroprotection with vinpocetine. Ideggyogy Sz. 2003; 56: 166-172.
60. Feigin V.L., Doronin B.M., Popova T.F. et al.: Vinpocetine treatment in acute ischaemic stroke: a pilot single-blind randomized clinical trial. Eur. J. Neurol. 2001; 8: 81-85.
61. Bereczki D., Fekete I.: Vinpocetine for acute ischaemic stroke. Cochrane Database Syst. Rev. 2000; 2: CD000480.
62. Solti F., Iskum M., Czakó E.: Effect of ethyl apovincaminate on the cerebral circulation. Studies in patients with obliterative cerebral arterial disease. Arzneimittelforschung 1976; 26: 1945-1947.
63. Miyazaki M.: The effect of cerebral vasodilator, vinpocetine, on cerebral vascular resistance evaluated by the Doppler ultrasonic technique in patients with cerebrovascular diseases. Angiology 1995; 46: 53-58.
64. Hadjiev D., Yancheva S.: Rheoencephalographic and psychological studies with ethyl apovincaminate in cerebral vascular insufficiency. Arzneimittelforschung 1976; 26: 1947-1950.
65. Feher G., Koltai K., Kesmarky G., Horvath B., Toth K., Komoly S., Szapary L.: Effect of parenteral or oral vinpocetine on the hemorheological parameters of patients with chronic cerebrovascular diseases. Phytomedicine 2009; 16: 111-117.
66. Szapáry L., Horváth B., Alexy T., Márton Z., Késmárky G., Szóts M., Nagy F. et al.: [Effect of vinpocetin on the hemorheologic parameters in patients with chronic cerebrovascular disease]. Orv. Hetil. 2003; 144: 973-978.
67. Hayakawa M.: Comparative efficacy of vinpocetine, pentoxifylline and nicergoline on red blood cell deformability. Arzneimittelforschung 1992; 42: 108-110.
68. Burtsev E.M., Savkov V.S., Shprakh V.V., Burtsev M.E.: [10-years experience with using Cavinton in cerebrovascular disorders]. Zh. Nevropatol. Psikhiatr. Im. S.S. Korsakova 1992; 92: 56-60.
69. Bereczki D., Fekete I.: Vinpocetine for acute ischemic stroke. Stroke 2008; 39: 2404-2405.
70. Salvemini D., Misko T.P., Masferrer J.L. et al.: Nitric oxide activates cyclooxygenase enzymes. Proc. Natl. Acad. Sci. USA 1993; 90: 7240-7244.
71. Olah V.A., Balla G., Balla J., Szabolcs A., Karmazsin L.: An in vitro study of the hydroxyl scavenger effect of Cavinton. Acta Paediatr. Hung. 1990; 30: 309-316.
72. Santos M., Duarte A., Moreira P., Oliveira C.: Synaptosomal response to oxidative stress: effect of vinpocetine. Free Radic. Res. 2000; 32: 57-66.
73. Gabryel B., Adamek M., Pudelko A., Malecki A., Trzeciak H.: Piracetam and vinpocetine exert cytoprotective activity and prevent apoptosis of astrocytes in vitro in hypoxia and reoxygenation. Neurotoxicology 2002; 23: 19-31.
74. Kolarov G., Orbetsova M., Nalbanski B. et al.: Complex effects of cavinton on climacteric symptoms. Akush. Ginekol. 2001; 42: 37-41.
75. Kiss E.: Adjuvant effect of cavinton in the treatment of climacteric symptoms. Ther. Hung. 1990; 38: 170-173.
76. Nekrassov V., Sitges M.: Vinpocetine protects from aminoglycoside antibiotic-induced hearing loss in guinea pig in vivo. Brain Res. 2000; 868: 222-229.
77. Maliavina U.S., Ovchinnikov I.U.M., Fasenko V.P., Maliev B.M., Kalinina M.V., Dadasheva B.B.: [Cavinton prevention of neurosensory hypoacousis in patients with different forms of tuberculosis]. Vestn. Otorinolaringol. 2003; 3: 35-40.
78. Jasper A.: Action of cavinton on hearing defects of different origin. Hung. Med. 1978; 26: 181-184.
79. Truss M., Stief C., Uckert S. et al.: Phosphodiesterase 1 inhibition in the treatment of lower urinary tract dysfunction: from bench to bedside. World J. Urol. 2001; 19: 344-350.
80. Truss M., Stief C., Uckert S. et al.: Initial clinical experience with the selective phosphodiesterase-I isoenzyme inhibitor vinpocetine in the treatment of urge incontinence and low compliance bladder. World J. Urol. 2000; 18: 439-443.
81. Csillik B., Mihály A., Knyihár-Csillik E.: Antinociceptive effect of vinpocetine – a comprehensive survey. Ideggyogy Sz. 2010; 63: 185-192.
82. Lohmann A., Dingler E., Sommer W., Schaffler K., Wober W., Schmidt W.: Bioavailability of vinpocetine and interference of the time of application with food intake. Arzneimittelforschung 1992; 42, 914-917.
83. Miskolczi P., Korma K., Polgar M., Vereczkey L.: Pharmacokinetics of vinpocetine and its main metabolite apovincaminic acid before and after the chronic oral administration of vinpocetine to humans. Eur. J. Drug. Metab. Pharmacokinet. 1990; 15: 1-5.
84. Vereczkey L.: Pharmacokinetics and metabolism of vincamine and related compounds. Eur. J. Drug. Metab. Pharmacokinet. 1985; 10: 89-103.
85. Skoromets A.A., Tanashian M.M., Chukanova E.I., Petrova E.A., Spirin N.N., Nikonov A.A., Peverennova I.E., Levin I.I.: [A multicenter program on assessment of efficacy and safety of a new therapeutic scheme for patients with chronic cerebrovascular insufficiency]. Zh. Nevrol. Psikhiatr. Im. S.S. Korsakova 2009; 109: 44-48.
86. Szakáll S., Boros I., Balkay L., Emri M., Fekete I., Kerényi L., Lehel S. et al.: Cerebral effects of a single dose of intravenous vinpocetine in chronic stroke patients: A PET study. J. Neuroimaging. 1998; 8: 197-204.
87. Charakterystyka Produktu Leczniczego Cavinton Forte 10 mg, tabletki; z dnia 23.04.2008.
88. Shimizu Y., Saitoh K., Nakayama M.: Agranulocytosis induced by vinpocetine. Medicine Online.
89. Akopov S.E., Gabrielian E.S.: Effects of aspiryn, dipyramidole, nifedipine and cavinton chich act on platet aggregation induced by diffrent aggregating agents alone and in combination. Eur. J. Clin. Pharmacol. 1992; 42: 257-259.
90. Hitzenberger G., Schmid R., Braun W., Grandt R.: Vinpocetine therapy does not change imipramine pharmacokinetics in man. Int. J. Clin. Pharmacol. Ther. Toxicol. 1990; 28: 99-104.
91. Grandt R., Braun W., Schulz H.U., Lührmann B., Frercks H.J.: Glibenclamide steady state plasma levels during concomitant vinpocetine administration in type II diabetic patients. Arzneimittelforschung 1989; 39: 1451-1454.
92. Storm G., Oosterhuis B., Sollie F.A.E., Visscher H.W., Sommer W., Beitinger H., Jonkman J.H.G.: Lack of pharmacokinetic interaction between vinpocetine and oxazepam. Br. J. Clin. Pharmcol. 1994; 38: 143-146.